News | October 13, 2022
Piramal Pharma Solutions launches ADCelerate
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines
The award was presented to Biocon Foundation as a mark of recognition of various projects undertaken during the year for reducing the environmental impact on cities
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Subscribe To Our Newsletter & Stay Updated
